San Diego Business Journal

SD HEALTHCARE

Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

George Uy Leaving Sorrento Therapeutics for New Startup

Sorrento Therapeutics Inc., a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced that George Uy, executive vice president and chief commercial officer, will leave the company at the end of July to join a startup as its chief executive officer.

Trovagene Aims to Raise $35M With Common Stock Offering

San Diego-based Trovagene Inc., a molecular diagnostics company, announced July 17 an offering of 4 million shares of its common stock, which is expected to bring in gross proceeds of around $35 million.

Tom Gruber Named New CEO at MyDx Inc.

MyDx Inc., creator of a handheld chemical analyzer for consumers, has appointed Tom Gruber as the new chief executive officer effective July 10, 2015.

Viviano’s Departure Won’t Slow UCSD Health’s Building Boom

UC San Diego Health System is losing its well-respected chief executive officer, Paul Viviano, but hospital officials say the loss won’t delay its building boom.

Tease photo

Sale of High-Flying Receptos Could Fuel More Innovation

BIOTECH: Talent Likely to Start New Ventures

In one of the largest sales of a San Diego biotech to date, New Jersey-based drug maker Celgene has agreed to purchase Receptos Inc. for $7.2 billion.

National Cancer Institute Awards IriSys 5-Year, $3M Contract

IriSys LLC, a San Diego-based pharmaceutical contract development and manufacturing organization, announced Wednesday that it was awarded a five-year contract worth up to $3 million by the National Cancer Institute (NCI).

AnaptysBio Raises $40 Million in Series D Round

AnaptysBio Inc., a company developing therapeutic antibodies for inflammation and immuno-oncology, announced Wednesday that it has raised $40 million in an oversubscribed Series D round.

Receptos Inc. Acquired by Celgene Corp. for $7.2 Billion

Receptos Inc., one of San Diego’s most promising biotech companies and a favorite or TheStreet's Jim Cramer, will be bought by New Jersey-based pharma giant Celgene Corp. for $7.2 billion.

aTyr Pharma Inc. President/COO Frederic Chereau Resigns

San Diego-based aTyr Pharma Inc., a public biotherapeutics company developing therapeutics to address severe rare diseases, announced Monday the resignation of President and Chief Operating Officer Frederic Chereau, effective immediately.

NuVasive Inc. Restructures Executive Team

NuVasive Inc., a public medical device company in San Diego, announced new executive appointments Monday following the appointment of Greg Lucier to chief executive earlier this year.

Medtronic Acquires Carlsbad-Based RF Surgical Systems for $235 Million

Carlsbad health tech firm RF Surgical Systems Inc. will be acquired by Dublin-based Medtronic for roughly $235 million, according to a recent press release.

Biotech Veterans Raise $4.2 Million in Debt Financing

A local biopharmaceutical company founded by biotech veterans Cam Garner and Ted Schroeder has raised $4.2 million in debt financing, according to a recent filing with the Securities and Exchange Commission.

Tease photo

Robert E. Hoffman Named CFO at AnaptysBio Inc.

AnaptysBio Inc., a company developing therapeutic antibodies for inflammation, announced Monday the appointment of Robert E. Hoffman as chief financial officer.

Tease photo

New Cell Sorter Aims to Fill Need for Speed and Availability

BIOTECH: Now in Beta Testing; Pre-Orders Could Start in the Fall

Imagine there were no affordable personal printers or scanners and you had to stand in line at Kinkos every time you needed to print or scan a document for a client. The costs could quickly become prohibitive.

Tri-City Medical Center Ends Partnership With Nifty After Fifty

Tri-City Medical Center and Nifty After Fifty LLC have come to a mutual agreement to terminate their relationship effective July 31, according to a spokesman for the Oceanside hospital. .